United States (USA) Insulin Delivery Devices Market Overview, 2031

In the United States, the increasing prevalence of diabetes has been a significant driver for the insulin delivery device market. As the number of people diagnosed with diabetes continues to rise, the demand for insulin and related delivery devices also increases. On-going advancements in insulin delivery device technology have played a crucial role in driving market growth. Innovations such as smart insulin pens, wearable insulin pumps, and continuous glucose monitoring systems have improved the ease of use, accuracy, and convenience for patients. There is a growing preference among patients for non-invasive or minimally invasive insulin delivery devices. This has led to the development of innovative devices that reduce the discomfort associated with traditional injection methods, such as insulin pumps and patch pumps. The integration of technology for remote patient monitoring and telemedicine has become more prevalent. Insulin delivery devices that are compatible with digital health platforms allow for real-time monitoring and better management of diabetes. The ageing population is more prone to diabetes, and as the demographic of elderly individuals grows, there is a corresponding increase in the demand for insulin and insulin delivery devices. Older individuals may find certain devices more convenient and easier to use, driving the market towards user-friendly solutions. With a trend towards home healthcare and self-management of chronic conditions, there is a growing demand for insulin delivery devices that are user-friendly and allow patients to administer insulin at home without the need for frequent visits to healthcare facilities. Innovations in drug delivery systems, not limited to insulin, can impact the insulin delivery device market. Technologies that enhance the bioavailability and efficacy of insulin may drive the adoption of specific delivery devices.

According to the research report, "" US Insulin Delivery Devices Market Overview, 2031,"" published by Bonafide Research, the US Insulin Delivery Devices market is anticipated to grow at more than 6.61% CAGR from 2026 to 2031. The rising incidence of diabetes and the rising cost of healthcare are the main causes of the market's rapid expansion. Furthermore, the market for these improved insulin delivery devices and equipment is expanding as a result of their acceptance. The US market for insulin delivery devices is being driven by significant R&D efforts in the production of several insulin-delivery device types. The United States market is expanding due to factors such as the increasing number of individuals with diabetes and the increased availability of technologically advanced devices. Nearly 29 million Americans suffer with diabetes. In terms of revenue, the North American region accounts for more than one-third of the market for insulin delivery devices. Since diabetes is affecting a greater number of people and is becoming more prevalent in the nation, the market for insulin delivery devices is expanding. Continuous technological advancements in insulin delivery devices have been a prominent trend. This includes the development of smart insulin pens, wearable insulin pumps, and integrated continuous glucose monitoring CGM systems. These technologies aim to improve accuracy, convenience, and patient adherence. The integration of AI and data analytics in diabetes management has gained traction. Insulin delivery devices that leverage these technologies can provide insights into patient behavior, predict blood glucose trends, and offer personalized recommendations for insulin dosing. Closed-loop systems, also known as artificial pancreas systems, have been gaining attention.

US insulin delivery devices market by product types is divided into insulin pens, insulin pump, insulin syringes and other insulin delivery services. In the U.S., devices for delivering insulin are divided into insulin pens, insulin pumps, insulin syringes, and other methods of delivery, each designed to meet various patient preferences, requirements, and clinical needs. Insulin pens capture the largest portion of the U.S. market thanks to their user-friendliness, precise dosing, portability, and enhancements in patient adherence. These devices are commonly used by individuals with Type 1 as well as Type 2 diabetes, particularly in home care and outpatient scenarios. Innovations such as smart insulin pens equipped with dose monitoring and connectivity features are paving the way for increased usage. Insulin pumps are an expanding segment, especially among patients with Type 1 diabetes and those who are tech-savvy. These pumps allow for continuous insulin infusion under the skin, which leads to improved blood sugar control and reduced hypoglycemia risks, making them favored even with higher initial and ongoing costs. Improvements in insurance coverage and increased awareness are promoting the adoption of pumps across the U.S. Insulin syringes, while traditional, remain a choice due to their affordability and availability, especially among patients watching their expenses and within certain clinical environments. Nevertheless, their market share is slowly decreasing as patients transition to using pens and pumps. Various alternative insulin delivery devices, like jet injectors and inhaled insulin systems, make up a smaller yet growing market. These devices attract patients who prefer delivery methods without needles, although their uptake is still limited due to issues related to cost, supply, and clinical requirements.

US insulin delivery devices market by disease types is divided into type 1 and type 2. The insulin delivery devices market in the U.S. is mainly classified by type of diabetes into Type 1 and Type 2, with each category showing different usage habits and drivers of demand. Individuals with Type 1 diabetes constitute a smaller segment of the population but show a high demand for sophisticated insulin delivery methods. Since insulin therapy is essential for managing Type 1 diabetes, these patients often use insulin pumps and advanced pens to maintain strict blood sugar control. Features like continuous delivery of insulin, links with continuous glucose monitoring systems, and digital health technologies are particularly vital for this group. Consequently, Type 1 diabetes significantly influences innovation and the uptake of premium devices in the U.S. market. On the other hand, Type 2 diabetes has a much larger population in the country, spurred by increasing rates of obesity, low activity levels, and an older demographic. Not all patients with Type 2 diabetes need insulin; however, those facing advanced or poorly managed conditions begin to rely more on insulin therapy. In this group, insulin pens and syringes are the most widely used due to their simplicity, lower costs, and suitability for occasional insulin use. Rising awareness, earlier initiation of insulin treatment, and enhanced reimbursement strategies are promoting the use of insulin devices among Type 2 diabetes patients. Both disease categories are essential for driving market expansion and shaping product development strategies in the U.S.

US insulin delivery devices market by end user is divided into home care setting, hospitals and clinics and other end users with home care settings having the largest share. The trend of managing diabetes at home is growing in the U.S., fueled by the convenience it offers to patients, lower costs, and improvements in easy-to-use insulin delivery systems. Insulin pens and pumps are especially appropriate for home use because they are straightforward, portable, and require little training. The increasing focus on self-management, aided by telehealth and remote monitoring, is boosting demand in this area. Hospitals and clinics form another major segment of end users, mainly for starting insulin therapy, training patients, providing urgent care, and dealing with complex cases. In these settings, insulin syringes, pens, and pumps are commonly utilized during both inpatient treatment and outpatient visits. Clinical settings also significantly contribute to teaching patients about using these devices, which affects long-term use. Other users, such as ambulatory surgical centers, long-term care homes, and nursing facilities, make up a smaller but consistent part of the market. The growth in this sector is encouraged by the increasing elderly demographic and the rise of diabetes-related health issues. The dynamics of end users in the U.S. show a strong move towards a more decentralized and patient-focused approach to insulin delivery.
"Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031
Aspects covered in this report
• Insulin Delivery Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By product Types
• Insulin Pens
• Insulin Pump
• Insulin Syringes
• Others Insulin Delivery Devices

By Disease Types
• Type 1
• Type 2

By End User
• Home care setting
• Hospitals & clinics
• Others End users “
Show more